|
US2013101585A1
|
|
Method of inhibiting osteoclast activity
|
|
AU2012202342A1
|
|
IL-1 zeta, IL-1 zeta splice variants and Xrec2 DNAS and polypeptides
|
|
JP2010043092A
|
|
Receptor that binds trail
|
|
US2009075886A1
|
|
Dendritic cell stimulatory factor
|
|
AU2007237257A1
|
|
Hematopoietin receptors HPR1 and HPR2
|
|
AU2007221823A1
|
|
IL-1 zeta, IL-1 zeta splice variants and Xrec2 DNAS and polypeptides
|
|
US2008254025A1
|
|
Human IL-1 epsilon DNA and polypeptides
|
|
IL184196D0
|
|
Receptor activator of nf-kappa b ligand (rankl) polypeptides and uses thereof
|
|
IL183048D0
|
|
Trail receptor polypeptide and dna encoding same
|
|
US2008166336A1
|
|
CD137 agonists to treat patients with IgE-mediated conditions
|
|
AU2007201172A1
|
|
Integrin antagonists
|
|
AU2007200686A1
|
|
Selection of cells expressing heteromeric polypeptides
|
|
US2007072249A1
|
|
Human cytokine and alpha-helix-containing polypeptides
|
|
US2006292144A1
|
|
Human disintegrin protein
|
|
AU2006202590A1
|
|
Methods for treating autoimmune and inflammatory conditions using antagonists of CD30 or CD30L
|
|
US2006154313A1
|
|
Human B7 polypeptide B7-H3A
|
|
AU2006200669A1
|
|
Claudin polypeptides
|
|
US2006078564A1
|
|
Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
|
|
US2006063256A1
|
|
Human regulatory T cells and uses thereof
|
|
AU2004290017A1
|
|
Antibodies that bind interleukin-4 receptor
|
